SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...

As of Wednesday, December 31, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 7.10%, which has investors ...

SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new ...

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In ...

SELLAS Life Sciences Group, Inc. (SLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.

SELLAS Life Sciences Group (SLS) is back on traders’ radar after fresh data from its leukemia program, including strong response rates and supportive FDA designations, helped spark a sharp move in the ...

NEW YORK, Nov. 30, 2023 /PRNewswire/ -- SOCOTEC USA, a leading provider of TIC (Testing, Inspection, and Certification), consulting, and advisory services with a strategic focus on buildings and ...